- Home
- EFSC vs CGON Comparison
EFSC vs CGON Comparison
Compare EFSC & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFSC
- CGON
- Stock Information
- Founded
- EFSC 1988
- CGON 2010
- Country
- EFSC United States
- CGON United States
- Employees
- EFSC N/A
- CGON N/A
- Industry
- EFSC Major Banks
- CGON
- Sector
- EFSC Finance
- CGON
- Exchange
- EFSC Nasdaq
- CGON NYSE
- Market Cap
- EFSC 2.2B
- CGON 2.3B
- IPO Year
- EFSC 1999
- CGON 2024
- Fundamental
- Price
- EFSC $59.25
- CGON $27.85
- Analyst Decision
- EFSC Strong Buy
- CGON Strong Buy
- Analyst Count
- EFSC 3
- CGON 10
- Target Price
- EFSC $67.33
- CGON $65.11
- AVG Volume (30 Days)
- EFSC 171.9K
- CGON 430.1K
- Earning Date
- EFSC 01-27-2025
- CGON 03-04-2025
- Dividend Yield
- EFSC 1.86%
- CGON N/A
- EPS Growth
- EFSC N/A
- CGON N/A
- EPS
- EFSC 4.83
- CGON N/A
- Revenue
- EFSC $607,337,000.00
- CGON $684,000.00
- Revenue This Year
- EFSC N/A
- CGON $158.34
- Revenue Next Year
- EFSC $2.14
- CGON N/A
- P/E Ratio
- EFSC $12.27
- CGON N/A
- Revenue Growth
- EFSC 3.73
- CGON 258.12
- 52 Week Low
- EFSC $37.28
- CGON $25.77
- 52 Week High
- EFSC $63.13
- CGON $47.78
- Technical
- Relative Strength Index (RSI)
- EFSC 48.08
- CGON 41.49
- Support Level
- EFSC $59.26
- CGON $27.10
- Resistance Level
- EFSC $61.29
- CGON $29.42
- Average True Range (ATR)
- EFSC 1.84
- CGON 1.15
- MACD
- EFSC -0.18
- CGON -0.10
- Stochastic Oscillator
- EFSC 30.21
- CGON 29.02
About EFSC Enterprise Financial Services Corporation
Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate, and consumer loans.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.